Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data

Matteo Bassetti; Valentina Zuccaro; Erika Asperges; Luigia Scudeller; Daniele Roberto Giacobbe

doi:10.1016/j.jinf.2022.08.003

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data

Matteo Bassetti, Valentina Zuccaro, Erika Asperges, Luigia Scudeller, Daniele Roberto Giacobbe,

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	573-607
Number of pages	35
Journal	The Journal of Infection
Volume	85
Issue number	5
Early online date	5 Aug 2022
DOIs	https://doi.org/10.1016/j.jinf.2022.08.003
Publication status	Published - Nov 2022

Access to Document

10.1016/j.jinf.2022.08.003

Cite this

@article{6efcc6802f474ebf9b021765a2b4dc6e,

title = "Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data",

author = "Matteo Bassetti and Valentina Zuccaro and Erika Asperges and Luigia Scudeller and Giacobbe, \{Daniele Roberto\} and \{de Lange\}, \{Prof.dr. D.W. (Dylan)\}",

note = "Funding Information: Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia, and speaker and/or advisory board fees from Pfizer and Tillotts Pharma. Outside the submitted work, MB reports research grants and/or advisor/consultant and/or speaker/chairman fees from Bayer, BioM{\'e}rieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. The other authors have no conflict of interests to disclose. ",

year = "2022",

month = nov,

doi = "10.1016/j.jinf.2022.08.003",

language = "English",

volume = "85",

pages = "573--607",

journal = "The Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "5",

}

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data. / Bassetti, Matteo; Zuccaro, Valentina; Asperges, Erika et al.
In: The Journal of Infection, Vol. 85, No. 5, 11.2022, p. 573-607.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients

T2 - An update including COVID-19 data

AU - Bassetti, Matteo

AU - Zuccaro, Valentina

AU - Asperges, Erika

AU - Scudeller, Luigia

AU - Giacobbe, Daniele Roberto

AU - de Lange, Prof.dr. D.W. (Dylan)

N1 - Funding Information: Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia, and speaker and/or advisory board fees from Pfizer and Tillotts Pharma. Outside the submitted work, MB reports research grants and/or advisor/consultant and/or speaker/chairman fees from Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. The other authors have no conflict of interests to disclose.

PY - 2022/11

Y1 - 2022/11

UR - https://www.scopus.com/pages/publications/85139704579

U2 - 10.1016/j.jinf.2022.08.003

DO - 10.1016/j.jinf.2022.08.003

M3 - Comment/Letter to the editor

C2 - 35934138

SN - 0163-4453

VL - 85

SP - 573

EP - 607

JO - The Journal of Infection

JF - The Journal of Infection

IS - 5

ER -

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data

Access to Document

Other files and links

Cite this